Methods for modulating angiogenesis of cancers refractory to anti-VEGF treatment
AssigneesInis Biotech LLC, Consejo Nacional De Investigaciones Cientificas Y Tecnicas, Fundacion Sales
InventorsGabriel Adrian Rabinovich, Diego Omar Croci Russo, Juan Pablo Cerliani, Mariana Salatino
Life of this patent
Estimating the term…
Abstract
A method for modulating angiogenesis in a cancer or tumor refractory to anti-VEGF, including identifying a cancer cell as being referactory to anti-VEGF, and then contacting the cancer cell refractory to anti-VEGF with an effective amount of an agent that modulates interaction between Gal1 or a Gal1 fragment and the natural binding partner of Gal1 or the Gal1 fragment to thereby modulate angiogenesis.
Claims16
A method for inhibiting angiogenesis in a cancer refractory to anti-VEGF, comprising:
- (a) identifying a cancer cell as refractory to anti-VEGF;
- and
- (b) contacting the refractory cancer cell with an effective amount of an agent that binds to galectin-1 (“Gal1”) to thereby inhibit angiogenesis in the refractory cancer cell, wherein the agent is an anti-Gal1 monoclonal antibody or antigen binding fragment thereof, wherein the anti-Gal1 monoclonal antibody or antigen binding fragment thereof comprises a heavy chain variable domain of SEQ ID NO:6 and a light chain variable domain of SEQ ID NO:11.
A method for treating a subject having a cancer refractory to anti-VEGF treatment, comprising:
- administering to the subject having the refractory cancer to the anti-VEGF treatment a therapeutically effective amount of Gal1 an anti-Gal1 monoclonal antibody or antigen binding fragment thereof, wherein the anti-Gal1 monoclonal antibody or antigen binding fragment thereof comprises a heavy chain variable domain of SEQ ID NO:6 and a light chain variable domain of SEQ ID NO:11.
A method for inhibiting angiogenesis in tumors refractory to anti-VEGF treatment, comprising administering to a subject in needed thereof having a cancer refractory to anti-VEGF treatment an effective amount of an anti-Gal1 monoclonal antibody or antigen binding fragment thereof, wherein the anti-Gal1 monoclonal antibody or antigen binding fragment thereof comprises a heavy chain variable domain of SEQ ID NO:6 and a light chain variable domain of SEQ ID NO:11.
Dependencies are inferred from the claim text.